#1 Clinical Trials Search in Europe

Clostridia, Cluster Iv, Strain Relative Anaerotruncus Colihominis, Live

This article examines two clinical trials investigating the use of live bacterial strains for treating different intestinal conditions. The first trial focuses on preventing recurrent Clostridioides difficile infection using VE303, while the second trial evaluates VE202 for treating mild to moderate ulcerative colitis. Both trials utilize capsules containing multiple strains of live bacteria to potentially improve gut health and manage these conditions.

Table of Contents

What is CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE?

CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE is a type of beneficial bacteria that is being studied as a potential treatment for certain gastrointestinal conditions. It is part of a group of bacteria known as live biotherapeutic products (LBPs), which are living microorganisms used to prevent, treat, or cure diseases in humans[1].

This particular strain is one of several bacterial strains included in two investigational drugs called VE303 and VE202. These drugs are being developed by Vedanta Biosciences, Inc. to help restore balance to the gut microbiome, which is the community of microorganisms living in our digestive tract[1][2].

How does it work?

The exact mechanism of action is still being studied, but it’s believed that CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE and other bacterial strains in VE303 and VE202 work by:

  • Colonizing the gut and helping to restore a healthy balance of bacteria
  • Competing with harmful bacteria for resources and space in the intestines
  • Potentially producing beneficial substances that support gut health
  • Interacting with the immune system to promote a healthy immune response

By promoting a healthy gut microbiome, these bacteria may help improve various gastrointestinal conditions[1][2].

What conditions does it treat?

CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE is currently being studied as part of two different treatments:

  1. VE303 for Clostridioides difficile infection (CDI): This drug is being investigated for the prevention of recurrent C. difficile infection. C. difficile is a type of bacteria that can cause severe diarrhea and other intestinal problems, especially after antibiotic use[1].
  2. VE202 for ulcerative colitis: This drug is being studied for the treatment of mild-to-moderate ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum[2].

Current Clinical Trials

Two major clinical trials are currently underway to study the effectiveness and safety of treatments containing CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE:

  1. VE303 for C. difficile infection: This is a Phase 3 study called the RestoratiVE303 Study. It aims to evaluate whether VE303 can prevent recurrent C. difficile infection in patients who have recently been treated for a C. difficile infection[1].
  2. VE202 for ulcerative colitis: This is a Phase 2 study investigating whether VE202 can improve symptoms and promote healing in patients with mild-to-moderate ulcerative colitis[2].

Both studies are randomized, double-blind, and placebo-controlled, which means that participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study[1][2].

How is it administered?

In both clinical trials, the treatments containing CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE are administered orally in the form of capsules. The specific dosing regimens are as follows:

  • VE303 for C. difficile infection: Participants take the capsules daily for 14 consecutive days[1].
  • VE202 for ulcerative colitis: Participants take the capsules for 8 weeks[2].

Potential Side Effects

As these treatments are still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are carefully monitoring participants for any adverse events. Some general considerations for live bacterial treatments include:

  • Mild digestive symptoms like gas or bloating as the gut adjusts to the new bacteria
  • Potential risk of infection, especially in people with weakened immune systems
  • Possible interactions with other medications, particularly antibiotics

It’s important to note that the clinical trials have specific inclusion and exclusion criteria to ensure the safety of participants. For example, people with certain medical conditions or those taking specific medications may not be eligible to participate[1][2].

Conclusion

CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE is a promising component of new treatments being developed for C. difficile infection and ulcerative colitis. While the research is still ongoing, these live biotherapeutic products represent an exciting new approach to treating gastrointestinal conditions by harnessing the power of beneficial bacteria. As always, it’s important to consult with a healthcare provider about the most appropriate treatments for your individual situation.

Aspect VE303 Trial VE202 Trial
Condition Recurrent Clostridioides difficile infection Mild to moderate ulcerative colitis
Main Objective Compare CDI recurrence rate at Week 8 Evaluate endoscopic response at Day 56
Treatment Duration 14 days 8 weeks
Age Range 12 years and older 18 to 75 years
Key Inclusion Criteria History of CDI within last 6 months UC diagnosis at least 3 months prior
Key Exclusion Criteria Recent probiotic or antibiotic use Previous biologic agent treatment for UC
Follow-up Period 24 weeks Not specified

FAQ

  • What are VE303 and VE202? VE303 and VE202 are investigational drugs containing multiple strains of live bacteria. VE303 is being studied for preventing recurrent C. difficile infection, while VE202 is being evaluated for treating mild to moderate ulcerative colitis.
  • How are these treatments administered? Both VE303 and VE202 are administered orally in capsule form. In the VE303 trial, patients take the capsules daily for 14 consecutive days. For VE202, patients take the capsules for 8 weeks.
  • What are the main goals of these clinical trials? The VE303 trial aims to compare C. difficile infection recurrence rates between VE303 and placebo groups. The VE202 trial's main goal is to evaluate the drug's efficacy in improving endoscopic response in ulcerative colitis patients after 8 weeks of treatment.
  • Who can participate in these trials? The VE303 trial includes patients aged 12 and older with a history of C. difficile infection. The VE202 trial is for adults aged 18-75 with mild to moderate ulcerative colitis diagnosed at least 3 months prior to the study.
  • Are there any notable exclusion criteria for these trials? Both trials exclude patients with certain gastrointestinal conditions, recent antibiotic use, and active infections. The VE202 trial also excludes patients who have previously received biologic agents or certain other treatments for ulcerative colitis.

Ongoing Clinical Trials on Clostridia, Cluster Iv, Strain Relative Anaerotruncus Colihominis, Live

  • Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Lithuania The Netherlands Poland

Glossary

  • Clostridioides difficile infection (CDI): A bacterial infection that can cause diarrhea and serious intestinal conditions, often occurring after the use of antibiotics.
  • Ulcerative colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, primarily affecting the colon and rectum.
  • Endoscopic response: An improvement in the appearance of the intestinal lining as observed through an endoscope, which is a tool used to examine the inside of the body.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Biologic agent: A type of medication made from living organisms or their products, used to treat various conditions including some forms of inflammatory bowel disease.
  • Fecal microbiota transplantation (FMT): A procedure in which fecal matter from a healthy donor is transferred to a patient to help restore a healthy balance of gut bacteria.
  • Probiotic: Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.
  • Standard of Care (SoC): The treatment approach that is accepted by medical experts as the most appropriate in a given situation.

References

  1. http://clinicaltrials.eu/trial/study-on-ve303-for-preventing-recurrent-c-difficile-infection-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-ve202-for-patients-with-mild-to-moderate-ulcerative-colitis/